ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1574

The Role of 18F-FDG PET/CT Scans in Takayasu Arteritis

Sahil Jain1, Abdulrahman Khormi2, Marcela Munoz-Urbano3, Shirish Sangle1 and David D'Cruz4, 1Louise Coote Lupus Unit, Guy's and St Thomas' Hospital NHS Foundation Trust, London, United Kingdom, 2Prince Sattam University Medical College, Al-Kharj, Saudi Arabia, 3Clínica Imbanaco, Cali, Colombia, 4Guy’s Hospital, Louise Coote Lupus Unit, London, United Kingdom

Meeting: ACR Convergence 2023

Keywords: Imaging, Takayasu.s arteritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1554–1578) Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Takayasu arteritis (TA) is a large-vessel vasculitis which primarily affects the aorta and its main branches. Accurate assessment of disease activity has always been challenging and inadequate treatment may result in irreversible damage. The Indian Takayasu Clinical Arteritis Scores (ITAS 2010, ITAS.A) are validated and reliable measures of disease activity. Positron-emission tomography (PET) and 18F-FDG PET with computed tomography (PET/CT) are non-invasive metabolic imaging modalities that have been proposed as important tools to assess disease activity.

Methods: We retrospectively studied 26 TA patients between January 2008 – March 2023. The diagnosis was confirmed on clinical, laboratory and imaging criteria. Disease activity as assessed by the ITAS 2010, clinical, laboratory and imaging techniques (including magnetic resonance imaging, Doppler ultrasound and/or digital subtraction angiography) was compared with the results of the PET/CT scans.

Results: Median age at TA diagnosis was 33 years (13-57). There were 22 females (84.6%), 4 males and Caucasians (61.5%), Asians (30.8%) and Afro-Caribbean (7.7%). Median follow up was 156 months (20 – 444). Thirteen of 26 patients (50%) had positive antiphospholipid antibodies (aPL). Two of the patients were diagnosed with obstetric anti-phospholipid syndrome (APS) and 1 with both thrombotic and obstetric APS.

Of 26 patients, there were 43 PET/CT scans performed in 22 patients. Ten patients had a single scan and 12 patients had 2 or more scans (maximum 4 scans). Nine scans were done for diagnosis and 34 during follow up. Of the 9 diagnostic scans, all 9 had clinically active disease (ITAS score ≥ 2), 8 (88.9%) had raised inflammatory markers (median ESR 57 (20 -115), median CRP 46 (1-126)) and 7 (77.8%) had a positive PET scan (suggestive of active vasculitis). Of the 34 follow up scans, 27 scans (in 17 patients) had clinically active disease (ITAS score ≥ 2) and 7 scans (in 6 patients) were in remission (ITAS score 0). Of the 27 scans with clinically active disease, 12 scans were positive (44.4%). In the remaining 15 scans, 11 (73.3%) were done while on steroids and/or immunosuppression (median prednisolone dose 5mg (2.5 – 10mg)). The 7 follow up scans in clinical remission and had no FDG uptake.

Conclusion: 18F-FDG PET/CT scanning is helpful as a diagnostic and monitoring tool to assess disease activity in TA. PET scan imaging correlates with ITAS activity. Corticosteroid therapy may negatively impact the PET scan result and results should be correlated carefully with clinical, laboratory and other radiological assessments. It remains unclear whether presence of aPL/APS is a clinically important association.

Supporting image 1


Disclosures: S. Jain: None; A. Khormi: None; M. Munoz-Urbano: None; S. Sangle: None; D. D'Cruz: Eli Lilly & Company, 2, GSK, 1, 2, UCB, 2, Vifor Pharma, 1.

To cite this abstract in AMA style:

Jain S, Khormi A, Munoz-Urbano M, Sangle S, D'Cruz D. The Role of 18F-FDG PET/CT Scans in Takayasu Arteritis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/the-role-of-18f-fdg-pet-ct-scans-in-takayasu-arteritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-role-of-18f-fdg-pet-ct-scans-in-takayasu-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology